OROliver M. Russell

Oliver M. Russell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Oliver M. Russell has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Strength training rescues mitochondrial dysfunction in skeletal muscle of patients with myotonic dystrophy type 1

    by Valeria Di Leo, Conor Lawless, Marie-Pier Roussel, Tiago B. Gomes, Gráinne S. Gorman, Oliver M. Russell, Helen A. L. Tuppen, Elise Duchesne, Amy E. Vincent

    Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder, for which no cure exists. This study investigates the effects of 12-week strength training on mitochondrial oxidative phosphorylation in skeletal muscle in a cohort of DM1 patients (n=11, males) in comparison to untrained sex-matched healthy subjects. Immunofluorescence was used to assess protein levels of key respiratory chain subunits of complex I (CI) and complex IV (CIV), and markers of mitochondrial mass and cell membrane in individual myofibers sampled from biopsies. We classified each patient myofiber as having normal, low or high levels of CI and CIV and compared the proportions of affected fibers before and after exercise training. The significance of changes observed between pre- and post-exercise training within patients was estimated using a permutation test. At baseline, DM1 patients present with significantly decreased mitochondrial mass, and isolated or combined CI and CIV deficiency. After strength training, in most patients a significant increase in mitochondrial mass was observed, and all patients showed a significant increase in CI and/or CIV protein levels. Remarkably, 12-week strength training is sufficient to partially rescue mitochondrial dysfunction in DM1 patients, suggesting exercise as an inexpensive and accessible therapy option.

  • Open Access

    Preferential amplification of a human mitochondrial DNA deletion in vitro and in vivo

    by Oliver M. Russell, Isabelle Fruh, Pavandeep K. Rai, David Marcellin, Thierry Doll, Amy Reeve, Mitchel Germain, Julie Bastien, Karolina A. Rygiel, Raffaele Cerino, et al.

    We generated induced pluripotent stem cells (iPSCs) from patient fibroblasts to yield cell lines containing varying degrees of heteroplasmy for a m.13514 A > G mtDNA point mutation (2 lines) and for a ~6 kb single, large scale mtDNA deletion (3 lines). Long term culture of the iPSCs containing a single, large-scale mtDNA deletion showed consistent increase in mtDNA deletion levels with time. Higher levels of mtDNA heteroplasmy correlated with increased respiratory deficiency. To determine what changes occurred in deletion level during differentiation, teratomas comprising all three embryonic germ layers were generated from low (20%) and intermediate heteroplasmy (55%) mtDNA deletion clones. Regardless of whether iPSCs harbouring low or intermediate mtDNA heteroplasmy were used, the final levels of heteroplasmy in all teratoma germ layers increased to a similar high level (>60%). Thus, during human stem cell division, cells not only tolerate high mtDNA deletion loads but seem to preferentially replicate deleted mtDNA genomes. This has implications for the involvement of mtDNA deletions in both disease and ageing.


  • Open Access

    Applying the Airbrakes: Treating Mitochondrial Disease with Hypoxia

    by Oliver M. Russell, Robert N. Lightowlers, Doug M. Turnbull


  • Open Access

    Potential compounds for the treatment of mitochondrial disease

    by P. K. Rai, O. M. Russell, R. N. Lightowlers, D. M. Turnbull

    Mitochondrial diseases are a group of heterogeneous disorders for which no curative therapy is currently available. Several drugs are currently being pursued as candidates to correct the underlying biochemistry that causes mitochondrial dysfunction. A systematic review of pharmacological therapeutics tested using in vitro, in vivo models and clinical trials. Results presented from database searches undertaken to ascertain compounds currently being pioneered to treat mitochondrial disease. Previous clinical research has been hindered by poorly designed trials that have shown some evidence in enhancing mitochondrial function but without significant results. Several compounds under investigation display poor pharmacokinetic profiles or numerous off target effects. Drug development teams should continue to screen existing and novel compound libraries for therapeutics that can enhance mitochondrial function. Therapies for mitochondrial disorders could hold potential cures for a myriad of other ailments associated with mitochondrial dysfunction such as neurodegenerative diseases.